First-in-class PI3Kα-targeting degrader antibody conjugates (DACs) for selective and safer treatment of PI3Kα-driven cancers

PI3Kα is a critical oncogenic driver in a broad range of solid tumors, including breast cancer, where activating mutations and pathway hyperactivation are frequently observed. Although two PI3Kα inhibitors have recently been approved by the FDA for breast cancer treatment, their clinical utility is significantly constrained by dose-limiting, on-target toxicities due to wild-type PI3Kα inhibition, […]